二氢-4,4-二甲基-2,3-呋喃二酮 | 13031-04-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 中文名称: 二氢-4,4-二甲基-2,3-呋喃二酮
• 中文别名: 去氢泛酸内酯；泛醇杂质D
• 英文名称: ketopantolactone
• 英文别名: 4,4-Dimethyl-dihydro-furan-2,3-dion；Dihydro-4,4-dimethyl-2,3-Furandione；4,4-dimethyloxolane-2,3-dione
• CAS: 13031-04-4
• 化学式: C₆H₈O₃
• mdl: MFCD00012331
• 分子量: 128.128
• InChiKey: HRTOQFBQOFIFEE-UHFFFAOYSA-N

物化性质

• 熔点：
  67-69 °C (lit.)
• 沸点：
  125-126℃ (15 Torr)
• 密度：
  1.152±0.06 g/cm3(Predicted)
• 溶解度：
  二氯甲烷：可溶25mg/mL，澄清，无色至黄色

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2932190090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Dihydro-4,4-dimethyl-2,3-furandione
CAS-No. : 13031-04-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C6H8O3
Molecular Weight : 128,13 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Hygroscopic.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 67 - 69 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

二氢-4,4-二甲基-2,3-呋喃二酮是一种杂环有机化合物，主要用作医药中间体。

反应信息

• 作为反应物：
  描述：

  二氢-4,4-二甲基-2,3-呋喃二酮 在 哌啶乙酸盐 、 β-丙氨酸 作用下， 以 甲苯 为溶剂， 反应 24.0h， 生成 5,5-dimethyl-2-oxo-5,6-dihydro-2H-pyran-3,4-dicarboxylic acid
  参考文献：
  名称：

  3-亚甲基二取代的 2-氧代-四氢呋喃的合成及其重排为 5,6-二氢-2H-吡喃-2-酮

  摘要：

  描述了由 α-酮内酯 1a、b 和 Knoevenagel 组分 2a-f 以及 3 和 4 合成 3-亚甲基二取代的 2-氧代四氢呋喃 5a-g 和 6-8。所用的催化剂是四氯化钛/吡啶、醋酸哌啶/β-丙氨酸和β-丙氨酸。5a-d、5f和6的开环和皂化得到5,6-二氢-2H-吡喃-2-9a-f。

  DOI：

  10.1002/ardp.19823150603
• 作为产物：
  描述：

  在 盐酸 作用下， 以 水 为溶剂， 生成 二氢-4,4-二甲基-2,3-呋喃二酮
  参考文献：
  名称：

  Process for producing intermediate furanones from diol derivative and

  摘要：

  描述了一种制造式为##STR1##的呋喃酮的新工艺。在这个工艺中，首先将二醇与氯化亚砜反应，然后形成的亚硫酸酯，经氧化成相应的硫酸酯后，与氰化钠反应，生成的羟基腈经水解。式I的呋喃酮可用作制造R-(-)-泛酸内酯的起始原料。

  公开号：

  US04596879A1
• 作为试剂：
  描述：

  (8alpha,9R)-10,11-二氢脱氧辛可宁-9-醇 在 二氢-4,4-二甲基-2,3-呋喃二酮 、 5% alumina-supported platinum catalyst 、 氢气 作用下， 以 甲苯 为溶剂， 24.84 ℃ 、5.0 MPa 条件下， 生成 1',2',3',4'(R),10,11-hexahydro-CD 、 1',2',3',4'(S),10,11-hexahyddro-CD 、 (R)-[(2S,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(5,6,7,8-tetrahydroquinolin-4-yl)methanol
  参考文献：
  名称：

  铂对映选择性加氢过程中辛可尼定的基质控制吸附

  摘要：

  通常接受的是，手性改性金属上对映异构的起源是通过改性剂的手性环境控制底物的吸附和反应性。在这里，我们为共同的过程提供了第一个实验证据，即，底物控制了辛可尼定（CD）在金属表面上的吸附和反应性。我们的方法是在存在或不存在活化的酮底物的情况下，对喹啉环（CD的锚固部分）进行竞争性氢化。在弱相互作用溶剂甲苯中的Pt / Al 2 O 3上，CD（和10,11-dihydro-CD）有利于C（4'-pro（S）的吸附几何形状，杂芳环的饱和度给出1'，2 ′，3′，4′（S），10,11-六氢-CD {（S）-CDH 6 }过量。如主要产物（R）-CDH 6所示，添加苯甲酰甲酸酯，酮戊内酯或丙酮酸乙酯会使CD的主要构象反转为C（4'）– pro（R），甚至比率高出约30％ （“配体逆加速度”）。与CD强烈相互作用的乙酸对喹啉加氢有相似的作用。与此相反，用弱CD产物α羟基酯相互作用，减速喹啉环的氢化和

  DOI：

  10.1016/j.jcat.2010.03.003

文献信息

• Cationic Rhodium(I)/H₈-binap Complex Catalyzed [2+2+2] Cycloadditions of 1,6- and 1,7-Diynes with Carbonyl Compounds
  作者：Yousuke Otake、Rie Tanaka、Ken Tanaka

  DOI：10.1002/ejoc.200900185

  日期：2009.6

  catalyzes [2+2+2] cycloadditions of a variety of 1,6- and 1,7-diynes with both electron-deficient and electron-rich carbonyl compounds, leading to dienones in high yield under mild reaction conditions. In the reactions with acyl phosphonates, the reactivity of 1,6- and 1,7-diynes was highly dependent on their own structures. The addition of chelating diethyl oxalate effectively promoted the [2+2+2] cycloadditions

  我们已经确定阳离子铑 (I)/H8-binap 络合物可催化各种 1,6- 和 1,7-二炔与缺电子和富电子羰基化合物的 [2+2+2] 环加成，导致在温和的反应条件下高产率的二烯酮。在与酰基膦酸酯的反应中，1,6- 和 1,7- 二炔的反应性高度依赖于它们自身的结构。螯合草酸二乙酯的添加有效地促进了涉及酰基膦酸酯的 [2+2+2] 环加成，这可能是由于二炔和酰基膦酸酯之间通过简单的配体交换平衡形成了所需的二炔和酰基膦酸酯的 1:1 铑配合物。弱配位的草酸二乙酯。在涉及双功能羰基化合物或不对称 1,6-二炔的反应中，观察到高化学或区域选择性。
• POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS
  申请人：He Wei

  公开号：US20160200730A1

  公开（公告）日：2016-07-14

  Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

  本文描述了一种新型的多氟取代吡唑嘧啶化合物或其盐。这些化合物是布鲁顿酪氨酸激酶（BTK）抑制剂。这些化合物可能具有更好的BTK抑制选择性和药代动力学特性。本文披露了这些化合物的合成方法。本文还披露了多氟取代苯甲酮和取代苯氧基苯的新型合成方法。还披露了包括上述BTK抑制剂的药物组合物。本发明还涉及包含上述化合物作为活性成分的药物配方。本发明还包括通过给予BTK抑制剂及其配方来治疗和抑制自身免疫疾病、过敏性疾病、炎症性疾病和癌症的治疗方法。
• Alkylidene Meldrum's Acids as Platforms for the Vinylogous Synthesis of Dihydropyranones
  作者：Stéphane Wittmann、Thomas Martzel、Cong Thanh Pham Truong、Martial Toffano、Sylvain Oudeyer、Régis Guillot、Chloée Bournaud、Vincent Gandon、Jean‐François Brière、Giang Vo‐Thanh

  DOI：10.1002/anie.202014489

  日期：2021.5.10

  Upon Brønsted base organocatalysis, ketone‐derived alkylidene Meldrum's acids proved to be competent vinylogous platforms able to undergo a formal (4+2) cycloaddition reaction with dihydro‐2,3‐furandione, providing an unprecedented route to 3,6‐dihydropyran‐2‐ones as spiro[4.5]decane derivatives with up to 98 % ee thanks to the commercially available Takemoto catalyst. Preliminary investigation showed

  在Brønsted碱进行有机催化后，酮衍生的亚烷基Meldrum的酸被证明是能够与二氢2,3,3-呋喃二酮进行正式（4 + 2）环加成反应的乙烯基平台，为3,6-二氢吡喃-2提供了前所未有的途径得益于商业上可买到的Takemoto催化剂，其为高达98％ee的螺[4.5]癸烷衍生物。初步研究表明，该反应可扩展至其他活化的酮，从而将这些亚烷基梅尔德鲁姆酸确立为乙烯基系列中的新型C4合成子。
• Enantioselective hydrogenation reactions with a full set of preformed and prepared in situ chiral diphosphine-ruthenium (II) catalysts.
  作者：J.P. Genêt、C. Pinel、V. Ratovelomanana-Vidal、S. Mallart、X. Pfister、L. Bischoff、M.C.Cano De Andrade、S. Darses、C. Galopin、J.A. Laffitte

  DOI：10.1016/0957-4166(94)80030-8

  日期：1994.4

  new class of 2-methylallyl ruthenium chiral diphosphines 1 are efficient in asymmetric hydrogenation of α,β unsaturated acids and allylic alcohols. The related chiral halogen-containing ruthenium catalysts 2 are prepared from 1 or in situ from (COD)Ru(η)3-(CH2)2CHCH3)2 by ligand exchange with the chelating diphosphine followed by protonation (HX) in acetone. This procedure allows rapid screening of chiral

  新型的2-甲基烯丙基钌手性二膦化合物1在α，β不饱和酸和烯丙醇的不对称加氢中有效。相关的手性含卤素的钌催化剂2由1或从（COD）Ru（η）3-（CH 2）2 CHCH 3）2原位制备。通过与螯合的二膦进行配体交换，然后在丙酮中进行质子化（HX）。该方法允许在钌介导的前手性底物氢化中快速筛选手性膦，例如Diop，Chiraphos，Cbd，Bppm，Binap，β-葡萄糖，Biphemp，MeO-Biphep，Me-Duphos。具有阻转异构体配体（ee高达99％）的Ru催化剂显示出很高的效率，并且C 2对称的双（膦环烷）也作为有价值的配体出现了（Me-Duphos，ee高达87％尚未优化）。β-酮酯的不对称氢化反应可以在相当温和的条件下进行（H 2为4 atm。（例如，在50℃，ee高达99％），具有双取代双键的β-酮酯也在控制的条件下以优异的光学纯度被化学选择性氢化为不饱和手性醇。
• Targeted Covalent Inhibition of <i>Plasmodium</i> FK506 Binding Protein 35
  作者：Thomas C. Atack、Donald D. Raymond、Christa A. Blomquist、Charisse Flerida Pasaje、Patrick R. McCarren、Jamie Moroco、Henock B. Befekadu、Foxy P. Robinson、Debjani Pal、Lisl Y. Esherick、Alessandra Ianari、Jacquin C. Niles、William R. Sellers

  DOI：10.1021/acsmedchemlett.0c00272

  日期：2020.11.12

  protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35

  FK506结合蛋白35，FKBP35，已被认为是必需的疟疾酶。雷帕霉素和FK506在培养的寄生虫中表现出抗疟原虫活性。然而，由于FKBP的结合口袋的高度保守的性质和这些药物的免疫抑制特性，需要选择性地抑制FKBP35并且缺乏不良副作用的化合物。与人FKBP相比，FKBP35在雷帕霉素结合口袋附近包含一个半胱氨酸C106，为开发靶向疟原虫FKBP35的共价抑制剂提供了机会。在这里，我们合成了FKBP35的抑制剂，表明它们在模型细胞环境中直接结合FKBP35，选择性地共价修饰C106，并在血阶段培养的寄生虫中表现出抗疟原虫活性。

表征谱图